We can’t show the full text here under this license. Use the link below to read it at the source.
Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Mazdutide lowers body weight in overweight or obese adults in a high-dose early-stage trial
AI simplified
Abstract
At Week 20, a mean weight loss of 20.0% was observed in adults receiving 16 mg of mazdutide.
- Weight loss of ≥15% was achieved by 66.7% of participants in Cohort 1 and 75.0% in Cohort 2, while no placebo participants achieved ≥5% weight loss.
- Mean percent change in waist circumference was -12.0% for Cohort 1 and -17.0% for Cohort 2 compared to -0.8% for placebo.
- Improved fasting metabolic biomarker profiles and reduced appetite were associated with mazdutide treatment.
- No serious adverse events were reported, and the most common adverse events were mild or moderate gastrointestinal disorders.
AI simplified
Key numbers
-20.0%
Mean Percent Weight Loss
Weight loss in Cohort 1 at Week 20 compared to baseline.
66.7% of 12
Participants Achieving ≥15% Weight Loss
Cohort 1 participants achieving ≥15% weight loss.
-12.0%
Mean Percent Change in Waist Circumference
Change in waist circumference for Cohort 1 at Week 20.